Evidence map›Paper›PMID 38509731›Full record

ArticleJournal of cellular and molecular medicine2024

Induced pluripotent stem cell-based assays recapture multiple properties of human astrocytes.

Hideki Nonaka, Takayuki Kondo, Mika Suga, Ryu Yamanaka, Yukako Sagara, Kayoko Tsukita, Naoko Mitsutomi, Kengo Homma, Ryuta Saito, Fumihiko Miyoshi and 3 more

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hideki NonakaiPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center (BRC), Kyoto, Japan.
Takayuki KondoiPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center (BRC), Kyoto, Japan.
Mika SugaiPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center (BRC), Kyoto, Japan.
Ryu YamanakaMitsubishi Tanabe Pharma Corporation, Yokohama, Japan.
Yukako SagaraiPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center (BRC), Kyoto, Japan.
Kayoko TsukitaiPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center (BRC), Kyoto, Japan.
Naoko MitsutomiMitsubishi Tanabe Pharma Corporation, Yokohama, Japan.
Kengo HommaMitsubishi Tanabe Pharma Corporation, Yokohama, Japan.
Ryuta SaitoMitsubishi Tanabe Pharma Corporation, Yokohama, Japan.
Fumihiko MiyoshiMitsubishi Tanabe Pharma Corporation, Yokohama, Japan.
Hiromitsu OhzekiMitsubishi Tanabe Pharma Corporation, Yokohama, Japan.
Masahiro OkuyamaMitsubishi Tanabe Pharma Corporation, Yokohama, Japan.
Haruhisa InoueiPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center (BRC), Kyoto, Japan.ORCID 0000-0003-4736-9537

Funding

Canon Foundation for Scientific ResearchHealth and Labor Sciences Research Grant JP21FC1015Japan Agency for Medical Research and Development JP22bm0104001Japan Agency for Medical Research and Development JP22bm0804034Japan Agency for Medical Research and Development JP23bm1423012Japan Agency for Medical Research and Development JP23bm1423014Japan Society for the Promotion of Science 21H02807Japan Society for the Promotion of Science 23K06927Uehara Memorial Foundation
6 · The paper itself

Abstract

The majority of the population of glial cells in the central nervous system consists of astrocytes, and impairment of astrocytes causes various disorders. It is useful to assess the multiple astrocytic properties in order to understand their complex roles in the pathophysiology. Although we can differentiate human astrocytes from induced pluripotent stem cells (iPSCs), it remains unknown how we can analyse and reveal the multiple properties of astrocytes in complexed human disease conditions. For this purpose, we tested astrocytic differentiation protocols from feeder-free iPSCs based on the previous method with some modifications. Then, we set up extra- and intracellular assessments of iPSC-derived astrocytes by testing cytokine release, calcium influx, autophagy induction and migration. The results led us to analytic methods with conditions in which iPSC-derived astrocytes behave as in vivo. Finally, we applied these methods for modelling an astrocyte-related disease, Alexander disease. An analytic system using iPSC-derived astrocytes could be used to recapture complexities in human astrocyte diseases.

Indexed as

AstrocytesInduced Pluripotent Stem CellsCell DifferentiationCells, CulturedCytokinesHumansNeurogenesisCytokinesAlexander diseaseastrocyteautophagycalciumcytokinedisease complexityinduced pluripotent stem cellsmigration

Identifiers

PMID38509731
PMCPMC10955154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.